Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{150150,
        author = {Sushil S. Kore and Vishweshwar M Dharashive and Suraj G. Malpani and Nilesh N. Shinde},
        title = {BIOSIMILAR THE NEW ERA OF THERAPTIC SCIENCE},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {7},
        number = {3},
        pages = {81-92},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=150150},
        abstract = {A bio-similar is an organic product that is endorsed in view of a demonstrating that it is exceptionally like an FDA-approved natural product. They are almost equal to generics as in they are endorsed alternates for particular bio-built actions, or biologics. Thus, biosimilars are "comparable yet not the same" or at the end of the day biosimilars are "the twin yet not the clone" to the initial biologic pioneer item. The obstacles with bio-similar are, they have a different origin, have identical therapeutic effect, may additionally have dissimilar side-effects and for this reason need testing. The European Medicines Agency (EMA) twisted into the principal directorial office to affirm a bio-similar. The Indian generics in manufacturing got its first massive break in 1984, when the US exceeded what is referred to as Hatch-Waxman act. Biosimilars market in India presently includes few biosimilars. India has effectively offered out to tap the rising open door in the biosimilars' space. Focal aim of bio similar offers definite increase in patient access to the biological therapy and health care charge. In India bio similar has engrossed large investments in the areas of research, clinical trials and manufacturing. A proper plan of pharmacovigilance, education, also scientific discussion for biologics and biosimilars would ensure an insincere rise in healthcare access and market sustainability. This paper seeks to collate and review all relevant available intelligence of the health and business potential of biosimilars. In doing so, it provides a visualization of the essential steps that are required to be taken for global biosimilar receiving.},
        keywords = {Biosimilars, EMA, Guideline’s, India Pharma Industry},
        month = {},
        }